No Data
Satsuma Pharmaceuticals Gains US FDA Approval for Atzumi Nasal Powder for Migraines
The Nikkei average is up about 70 yen, after a round of buying, it is heavy on the upside due to selling while waiting for a pullback = morning of May 1.
On May 1st at 10:18 AM, the Nikkei Average was trading around 36,110 yen, up about 70 yen from the previous day. At 9:13 AM, it reached 36,341.62 yen, up 296.24 yen. In the US market on April 30th local time, while the Nasdaq Composite Index fell, the NY Dow rebounded after an early decline, marking its seventh consecutive day of gains. The impact of the negative growth in Q1 GDP (Gross Domestic Product) was countered. The effect on the Nikkei Average is significant from the SOX (Philadelphia Semiconductors).
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
Focus on Amano and Tirado [Today's Individual Stock Trends]
In the U.S. stock market on the 21st, the Dow Jones Industrial Average dropped by 971.82 points to 38,170.41, the Nasdaq Composite Index fell by 415.55 points to 15,870.90, and the Chicago Nikkei 225 Futures decreased by 105 yen from the day in Osaka to 34,155 yen. The exchange rate is 1 dollar = 140.80-90 yen. In today's Tokyo market, Amano <6436> revised up its earnings and Dividends forecast for the fiscal year ending March 2025, Tsubaki <7236> revised up its earnings forecast for the same fiscal year, and the company's own shares account for 5.48% of the total outstanding shares.
Stocks News Premium = Support for resolving "Drug Loss", marking related Stocks with support for clinical trials of new drugs overseas.
To resolve the 'drug loss' issue, which prevents the use of new drugs approved overseas but not in Japan, the government will support early commercialization through clinical trial assistance. There is a desire to mark related stocks. <M&A is also frequent> In Japan, the time until new drugs are approved is relatively long, and due to issues such as clinical trial costs and profitability, overseas Drug Manufacturers may not aim to enter. Many new drugs in this state of drug loss exist, and patient groups are seeking improvements.
The Nikkei average dropped significantly, down 1,023 yen, with a decrease in the margin as trading came to a close on the 11th in the afternoon session.
On the 11th, the Nikkei Stock Average in the afternoon session sharply fell by 1,023.42 yen from the previous day, closing at 33,585.58 yen. The TOPIX (Tokyo Stock Price Index) also declined by 72.49 points, reaching 2,466.91 points. On the 10th, the U.S. government announced that the tariffs imposed on China would total 145% instead of the previously stated 125%. In response, concerns over the escalation of U.S.-China trade friction heightened, leading to a sharp drop in the U.S. stock market on the 10th, with the Dow Inc and the Nasdaq Composite Index experiencing significant declines. Japanese stocks also plummeted following the sharp drop of U.S. stocks.
